Sunday, September 27, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· December 24, 2025

Communiqué de presse : Sanofi fait le point sur la soumission réglementaire du tolebrutinib dans la sclérose en plaques secondaire progressive non-récurrente

View original at globenewswire.com
Communiqué de presse : Sanofi fait le point sur la soumission réglementaire du tolebrutinib dans la sclérose en plaques secondaire progressive non-récurrente Sanofi fait le point sur la soumission réglementaire du tolebrutinib dans la sclérose en plaques secondaire progressive non-récurrente Paris, le 24 décembre 2025…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Disability progression remains a major unmet medical need in multiple sclerosis

    80% confidence

  • Impairment test result will have no impact on net income from activities/earnings per share from activities, and financial guidance for 2025 remains unchanged

    80% confidence

  • Sanofi is a biopharmaceutical company that innovates in R&D and leverages AI at scale to improve people's lives and achieve long-term growth

    80% confidence

  • Sanofi is very disappointed by FDA's action

    80% confidence

  • Sanofi remains committed to working with FDA to find a path forward for tolebrutinib and ultimately serve the MS patient community

    80% confidence

  • FDA's decision represents a significant and important policy reversal from previous feedback the agency had given to Sanofi

    80% confidence

  • FDA should consider input from scientific experts, clinicians and patients on this matter to ensure all perspectives are considered

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Vertical AI Agents Attract a Funding Wave Across Fintech-Adjacent Industries
A cluster of AI-native startups applying autonomous agents to narrow, operational problems — hotel front-desk staffing (Dextr AI), identity/fraud risk for financial institutions (Baselayer), insurance distribution (Napo, Connie Health, MGT Insurance) — closed seed-to-Series A rounds within days of each other in September 2026, with CB Insights running a coordinated CEO interview series to spotlight them. The pattern points to agentic AI maturing from generic chat tools into vertical, revenue-generating products, with identity verification for AI agents themselves (Baselayer) emerging as a new fintech infrastructure category responding directly to AI-driven fraud risk.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,984
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,984 facts checked against source5,306 source documents archived
Query this data → isubstrate.com
Communiqué de presse : Sanofi fait le point sur la soumission réglementaire du tolebrutinib dans la sclérose en plaques secondaire progressive non-récurrente — Source | Via News | Via News